- Home
- DXYZ vs LCTX Comparison
DXYZ vs LCTX Comparison
Compare DXYZ & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- LCTX
- Stock Information
- Founded
- DXYZ N/A
- LCTX 1990
- Country
- DXYZ
- LCTX United States
- Employees
- DXYZ N/A
- LCTX N/A
- Industry
- DXYZ
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXYZ
- LCTX Health Care
- Exchange
- DXYZ Nasdaq
- LCTX Nasdaq
- Market Cap
- DXYZ 313.1M
- LCTX 274.0M
- IPO Year
- DXYZ 2024
- LCTX N/A
- Fundamental
- Price
- DXYZ $26.39
- LCTX $1.39
- Analyst Decision
- DXYZ
- LCTX Strong Buy
- Analyst Count
- DXYZ 0
- LCTX 4
- Target Price
- DXYZ N/A
- LCTX $4.25
- AVG Volume (30 Days)
- DXYZ N/A
- LCTX 1.3M
- Earning Date
- DXYZ N/A
- LCTX 11-13-2025
- Dividend Yield
- DXYZ N/A
- LCTX N/A
- EPS Growth
- DXYZ N/A
- LCTX N/A
- EPS
- DXYZ N/A
- LCTX N/A
- Revenue
- DXYZ N/A
- LCTX $10,914,000.00
- Revenue This Year
- DXYZ N/A
- LCTX N/A
- Revenue Next Year
- DXYZ N/A
- LCTX $178.80
- P/E Ratio
- DXYZ N/A
- LCTX N/A
- Revenue Growth
- DXYZ N/A
- LCTX 76.43
- 52 Week Low
- DXYZ N/A
- LCTX $0.37
- 52 Week High
- DXYZ N/A
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- DXYZ 39.32
- LCTX 67.78
- Support Level
- DXYZ $26.00
- LCTX $1.20
- Resistance Level
- DXYZ $27.95
- LCTX $1.42
- Average True Range (ATR)
- DXYZ 1.03
- LCTX 0.07
- MACD
- DXYZ 0.18
- LCTX 0.01
- Stochastic Oscillator
- DXYZ 18.30
- LCTX 87.50
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.